Not exact matches
The
data was obtained from the Kuopio Osteoporosis Risk Factor and Prevention (OSTPRE) Study, which has been investigating the effects of various risk and protective factors
on bone density and
bone fractures since 1989.
The researchers drew
on data from the
Bone Mineral
Density in Childhood Study (BMDCS), funded by the NIH.
Because loss of
bone mineral
density is known to occur
on spaceflight missions, we need more
data regarding health effects, including
bone health, with long - term use of hormone treatments not just for contraception (as most women use them), but also for the less - common use to suppress menses.»
It's a «big
data» project that is yielding terabytes of information
on physiological markers of health including cardiac function, metabolism,
bone density, body composition, activity and blood pressure, among others.
Potential cardioprotection was based
on generally supportive
data on lipid levels in intermediate outcome clinical trials, trials in nonhuman primates, and a large body of observational studies suggesting a 40 % to 50 % reduction in risk among users of either estrogen alone or, less frequently, combined estrogen and progestin.2 - 5 Hip fracture was designated as a secondary outcome, supported by observational
data as well as clinical trials showing benefit for
bone mineral
density.6, 7 Invasive breast cancer was designated as a primary adverse outcome based
on observational
data.3, 8 Additional clinical outcomes chosen as secondary outcomes that may plausibly be affected by hormone therapy include other cardiovascular diseases; endometrial, colorectal, and other cancers; and other fractures.3, 6,9